Phase III randomized double-blind placebo-controlled multi-centre study assessing the efficacy and safety of durvalumab versus placebo as treatment following SBRT in patients with Stage I/II non small cell lung cancer.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
